Corrigendum to “Blockade of miR-3614 maturation by IGF2BP3 increases TRIM25 expression and promotes breast cancer cell proliferation” [EBioMedicine 41 (2019) 357–369]

The authors found that the published version of this article had repeated images in Fig. 6b. The images of Fig. 6b Ctrl and Scr-anti-miR used the same images. In addition, in Fig. 7d the images of Fig. 7d LV-si-Ctrl case1 and case3 share common areas. These unintentional mistakes were made because we posted the incorrect pictures when editing PDF image files. We have presented the corrected Figs. 6b and 7d as below.

Fig. 6.

MiR-3614-3p suppresses BC cell proliferation. (a, b) MTT cell proliferation assay and colony formation were performed at the indicated time points after transfection with pre-miR-3614, anti-miR-3614, or negative control. Data are presented as the mean ± SEM. (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ANOVA analysis). (c) miR-3614-3p increases G1 phase arrest in BC cells. Flow cytometry analysis of BC cells transfected with pre-miR-3614, anti-miR-3614, or negative control treatment. Data are presented as the mean ± SEM. (∗P < 0.05, ∗∗P < 0.01, ANOVA analysis). (d) The expression of CDK4, CyclinD1, and β-actin analyzed by Western blot after transfection with pre-miR-3614, anti-miR-3614, or negative control. (e) Xenograft studies show suppressed tumor growth when pre-miR-3614 is overexpressed in the transplanted cells. Gross morphology of tumors after 30 days of implantation with either LV-miR-3614 or LV-Ctrl cells (n = 3) (left). Tumor growth curves of the tumor volumes represent measurement taken every 3 d for 30 d (right). Data are shown as mean ± SEM (∗P < 0.05, Student's t-test).

Fig. 7.

IGF2BP3-depleted inhibits BC cell proliferation. (a, b) MTT assay and colony formation were performed at the indicated time points after transfection with LV-si-IGF2BP3 or related control. Data are presented as the mean ± SEM. ∗P < 0.05, ∗∗P < 0.01 (Student's t-test and ANOVA analysis). (c) Xenograft experiments showing suppressed tumor growth in response to IGF2BP3 knock-down. Gross morphology of tumors after 30 days of injection of either MCF-7/MDA-MB-231-LV-si-IGF2BP3 or MCF-7/MDA-MB-231-LV-si-Ctrl cells (n = 3) (left). Tumor growth curves of the tumor volumes represent measurements taken every 3 d for 30 d (right). Data are shown as mean ± SEM (∗P < 0.05, Student's t-test). (d) IHC staining of TRIM25 (right) and IGF2BP3 (left) in tumor tissues from mice implanted with MCF-7/MDA-MB-231-LV-si-IGF2BP3 or MCF-7/MDA-MB-231-LV-si-Ctrl cells. Magnification × 40. Scale bar, 50 μm. (e) MTT assay of BC cells after co-treatment with miR-3614-3p, si-IGF2BP3, TAM, and E2. Data are presented as the mean ± SEM. ∗P < 0.05, ∗∗P < 0.01 (Student's t-test).

These corrections do not change the description and original conclusions of this article. The authors sincerely apologize for any inconvenience caused by these mistakes.